Market capitalization | $2.85m |
Enterprise Value | $8.54m |
P/E (TTM) P/E ratio | 10.94 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 18.98 |
P/S ratio (TTM) P/S ratio | 6.33 |
P/B ratio (TTM) P/B ratio | 0.65 |
Revenue (TTM) Revenue | $450.00k |
EBIT (operating result TTM) EBIT | $-8.25m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast BiondVax Pharmaceuticals Ltd. Sponsored ADR:
1 Analyst has issued a forecast BiondVax Pharmaceuticals Ltd. Sponsored ADR:
Sep '24 |
+/-
%
|
||
Revenue | 0.45 0.45 |
-
|
|
Gross Profit | -1.65 -1.65 |
-
|
|
EBITDA | -7.01 -7.01 |
-
|
EBIT (Operating Income) EBIT | -8.25 -8.25 |
28%
28%
|
Net Profit | 3.63 3.63 |
140%
140%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases. It works on M-001, a synthetic peptide-based protein targeting both seasonal and pandemic strains of the influenza virus. The company was founded by Ron Babecoff and Rami Epstein on July 22, 2003 and is headquartered in Jerusalem, Israel.
Head office | Israel |
CEO | Amir Reichman |
Employees | 31 |
Founded | 2003 |
Website | www.scinai.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.